Lasso’s Spintech launches high-protein snacks in the GLP-1 era

Foodtech company Lasso is launching two CPG (consumer packaged goods) brands Froobies and CronchClub — snacks that deliver clean ingredients while being high in protein and fiber. 

The products are the first to use “Lasso’s Spintech,” integrating simple ingredients into packaged food products. It weaves together fiber and protein, removing the need for artificial additives, binders, or excess sugar.

Froobies is a fruit snack suitable for children and adults with nutritional benefits. Each package contains 4 g of protein and 3 g of fiber, with no added sugar, artificial flavors, or dyes.

CronchClub is a crisp, high-protein snack with 21–23 g of protein and 7–8 g of fiber, in the flavors Original, Herby Ranch, Garden Salsa, and Zesty BBQ. Lasso explains that rather than adding protein and fiber coatings, the macronutrients are directly woven into the crisps.

The two CPG innovations come at a time when healthy, nutritious snacks are in greater demand.

“We’re in the middle of a structural shift in how consumers approach food — a convergence of GLP-1 driven awareness and broader economic pressures that are reshaping expectations around nutrition and value,” says Lasso’s CEO Mike Messersmith.

“Consumers want real innovation, not legacy brands repackaging familiar formulas with added protein and calling it progress. Today’s shoppers are more informed and expect meaningful improvements in ingredients, nutrition, and formulation, and they want it now.”

Creating a need in a growing market

Earlier this month, Nutrition Insight sat down with leading industry suppliers to map out how the GLP-1 era is reshaping product development and ingredient strategy while examining how the industry can help brands meet the changing consumer demands in this fast-moving market. Recent research from Tate & Lyle found that one in three US citizens surveyed has used a GLP-1 medication, positioning a significant trend that nutrition brands must meet.

“Traditional food innovation cycles weren’t designed to move at that pace,” asserts Messersmith. “Because we’ve invested in proprietary technology from day one, we can bring new concepts to market in months, not years, and Froobies and CronchClub are proof. This is just the beginning.” 

The rise of GLP-1 receptor agonists such as semaglutide has thinned the waistlines of millions and opened the door for innovation in the US$200 billion supplement and nutraceutical industry. As the accessibility of drugs like Ozempic and Wegovy increases, users are eating less and discovering the biological effects of rapid weight loss.

Weight-loss drugs interfere with hunger cues and cause users to eat less. Experts urge nutritional guidance to avoid micronutrient inefficiency, loss of lean muscle mass, and other potential long-term health impacts. There is a push for the industry to innovate and bring products to the market that meet this need.